Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population‐based cohort study 1977‐2011

Sørensen, Jakob Ørskov; Nielsen, Ole Haagen; Andersson, Mikael; Ainsworth, Mark; Ytting, Henriette; Belard, Erika; Jess, Tine

doi:10.1111/liv.13548

Cited by 60 publications

(54 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 70% of patients with PSC have or will develop concurrent IBD, of which the majority, about 80%, will suffer from ulcerative colitis (UC). [2][3][4] Conversely, the presence of PSC among the total population of patients with IBD is rare, with a prevalence varying between 1.7-3.8%. 5,6 It has been proposed that IBD in PSC represents a distinct phenotype, characterised by a higher frequency of pancolitis with involvement of the right colon and a relatively mild disease course, and a higher occurrence of pouchitis after colectomy, compared to IBD without PSC.…”

Section: Introductionmentioning

confidence: 99%

Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis

Krijger

Wildenberg

Jonge

et al. 2019

Journal of Hepatology

View full text Add to dashboard Cite

Primary sclerosing cholangitis (PSC) is an inflammatory disease of the biliary tree, characterised by stricturing bile duct disease and progression to liver fibrosis. The pathophysiology of PSC is still unknown. The concurrence with inflammatory bowel disease (IBD) in about 70% of cases has led to the hypothesis that gut-homing lymphocytes aberrantly traffic to the liver, contributing to disease pathogenesis in patients with both PSC and IBD (PSC-IBD). The discovery of mutual trafficking pathways of lymphocytes to target tissues, and expression of gut-specific adhesion molecules and chemokines in the liver has pointed in this direction. There is now increasing interest in using drugs that intervene with these trafficking pathways (e.g. vedolizumab, etrolizumab) for the treatment of PSC-IBD. In this review we discuss what is currently known about the immunological interactions between the gut and the liver in concomitant PSC and IBD, as well as potential therapeutic options for intervening in these mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis

Krijger

Wildenberg

Jonge

et al. 2019

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…Up to 50% of these cases are recorded in the first year of diagnosis of PSC (10). The presence of chronic inflammation of bile ducts typically associated with PSC is thought to be one of the reasons for this heightened risk (11)(12)(13). Other factors that serve as the link between PSC and CCA include increased proliferation of the epithelial cells of the biliary tree, cholestasis in the ducts leading to the liver and presence of mutagens produced in the bile (10,11).…”

Section: Primary Sclerosing Cholangitis (Psc)mentioning

confidence: 99%

“…Other factors that serve as the link between PSC and CCA include increased proliferation of the epithelial cells of the biliary tree, cholestasis in the ducts leading to the liver and presence of mutagens produced in the bile (10,11). The role of inflammation in the growth and rapid development of CCA is also underscored by studies that identify inflammatory bowel disease (IBD) as one of the risk factors of CCA (12,13).…”

Section: Primary Sclerosing Cholangitis (Psc)mentioning

confidence: 99%

Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms

2019

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA), or cancer of the biliary epithelium is a relatively rare but aggressive form of biliary duct cancer which has a 5-year survival rate post metastasis of 2%. Although a number of risk factors are established for CCA growth and progression, a careful evaluation of the existing literature on CCA reveals that an inflammatory environment near the biliary tree is the most common causal link between the risk factors and the development of CCA. The fact that inflammation predisposes affected individuals to CCA is further bolstered by multiple observations where the presence and maintenance of an inflammatory microenvironment at the site of the primary tumor plays a significant role in the development and metastasis of CCA. In addition, mechanisms activating the tumor vasculature and enhancing angiogenesis and lymphangiogenesis significantly contribute to CCA aggressiveness and metastasis. This review aims to address the role of an inflammatory microenvironment-CCA crosstalk and will present the basic concepts, observations, and current perspectives from recent research studies in the field of tumor stroma of CCA.

show abstract

“…В большинстве случаев (72%) это были пациенты с ЯК, и у 78% из них отмечалось тотальное поражение. У 91% пациентов с ПСХ и болезнью Крона отмечалось поражение толстой кишки [3]. Анкилозирующий спондилит при ВЗК чаще встречается у мужчин и чаще при болезни Крона (2,7%) [1].…”

Section: Introductionunclassified

Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis)

2020

View full text Add to dashboard Cite

Ulcerative colitis and Crohn’s disease are severe immune-mediated diseases. Extraintestinal manifestations of inflammatory bowel disease (IBD) significantly increase the burden to the patient. The most common extraintestinal manifestations include erythema nodosum, ankylosing spondylitis, and primary sclerosing cholangitis. Some of the extraintestinal manifestations depend on the activity of the inflammatory process in the intestine and can be reversed during treatment of IBD, while the others require specific therapy, since it does not depend on the degree of inflammation in the intestine. Patients with IBD are at increased risk of developing complications caused by other organ systems, such as osteoporosis, venous thromboembolism, and cardiovascular diseases. Immunemediated diseases such as multiple sclerosis and psoriasis have been associated with inflammatory bowel disease, but these conditions can also be complications of IBD therapy. In this regard, patients and healthcare providers should exercise vigilance in identifying extraintestinal manifestations and complications of IBD, and the therapy should be aimed both at treating the underlying disease and reversing extraintestinal manifestations as much as possible. Interleukin-12/23 is an important cytokine in the inflammatory process development in the immune-mediated diseases. Ustekinumab is effective in treating not only IBD, but also psoriasis by blocking interleukin 12/23. The drug shows a higher survival index of the therapy as compared to tumour necrosis factor-α inhibitors. The article describes the experience of using ustekinumab in severe concomitant pathology – Crohn’s disease in the form of ileocolitis and psoriasis vulgaris with initial manifestations of psoriatic arthritis against ineffectiveness of tumour necrosis factor-α inhibitors.

show abstract

Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population‐based cohort study 1977‐2011

Abstract: This unselected population-based study shows that PSC-IBD patients not only have an extensive phenotype of IBD, they are also treated more intensively than other patients with IBD. However, the prognosis remains poor and without any apparent improvement over calendar time.

Cited by 60 publications

References 40 publications

Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis

Return to sender: Lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis

Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms

Ustekinumab in patients with Crohn’s disease with extraintestinal manifestations (psoriasis)

Contact Info

Product

Resources

About